Latin America Autoinjectors Market Overview

The Latin America Autoinjectors Market was valued at USD 734.48 Million in 2025 and is projected to reach USD 2,507.54 Million by 2035, growing at a CAGR of 13.06%. It is the fourth-largest of the five regions in the Global Autoinjectors Market report, and the one where the diagnosis-gap conversion story, widening insurance coverage of biologics and pooled public procurement matter most to how — and how fast — autoinjector-delivered therapies reach patients.

Brazil is the region's regulatory and commercial reference market: ANVISA oversees medicines, devices and combination products, and CMED regulates drug prices, so regional launch sequencing typically begins there and Brazilian formulary and procurement decisions are the region's leading indicator. Argentina, Colombia and Chile maintain their own national frameworks with local registration requirements, and the PAHO Strategic Fund provides pooled procurement for lower-income markets. This report quantifies the region across twelve segmentation axes and 27 segment tables, with dedicated analysis for Brazil, Argentina, Colombia, Chile and the Rest of Latin America. (Mexico is covered in the North America Autoinjectors Market report.)

Latin America Autoinjectors Market by Country

• Brazil — USD 357.69 Million in 2025 to USD 1,243.04 Million by 2035 (13.27% CAGR); nearly half of regional revenue (48.7%). Demand converts through the same diagnosis-gap mechanism analysed for the emerging-market opportunity, and Brazil's formulary and procurement decisions lead the region.
• Rest of Latin America — USD 161.07 Million to USD 534.48 Million (12.74% CAGR); the region's largest single line after Brazil, reflecting how widely distributed remaining demand is, with WHO prequalification and PAHO pooled procurement the most relevant access mechanisms.
• Argentina — USD 83.44 Million to USD 264.11 Million (12.21% CAGR); macroeconomic volatility makes device affordability, and therefore the low-cost end of the architecture spectrum, disproportionately relevant.
• Colombia — USD 68.09 Million to USD 247.93 Million (13.80% CAGR); the fastest-growing country in the region as insurance coverage of biologic therapy widens.
• Chile — USD 64.19 Million to USD 217.99 Million (13.00% CAGR); the region's highest-income per-capita market, with earlier adoption of premium presentations relative to its size.

What Shapes the Latin American Market

Biosimilars and generic GLP-1 arrive first. In July 2026 Sun Pharma received ANVISA approval to manufacture and market generic semaglutide injection in Brazil, expanding its complex-injectable and GLP-1 presence in Latin America, and Zydus Lifesciences secured COFEPRIS biosimilar approvals in Mexico. Because Latin American markets are price-sensitive, biosimilar and generic presentations — each requiring its own device — are the primary route by which autoinjector volume grows. Endocrinology, metabolic and hormonal disorders is the region's fastest-growing therapy area at 13.75% CAGR, reaching USD 426.14 Million by 2035.

Affordability decides the architecture. Low-cost, drug-agnostic devices such as Owen Mumford Autoject 2 and user-loaded standard-syringe architectures matter more here than in North America or Europe, which is why the report quantifies those categories separately. Up to 1.0 mL containers hold USD 1,872.74 Million by 2035, but over-2.25 mL formats grow fastest at 14.20% as large-volume biologics arrive through the biosimilar channel.

Global capacity serves the region. Latin America has limited local autoinjector manufacturing; supply comes from the platform specialists' multi-continent footprints — SHL Medical has shipped more than 1.5 billion autoinjectors from Taiwan, Switzerland and the U.S., and Ypsomed, Owen Mumford, Gerresheimer and Nemera supply the multinational pharma base. The IDF Diabetes Atlas and WHO Essential Medicines List listing of GLP-1 receptor agonists frame the region's untreated demand.

Latin America Segment Insights

Monoclonal antibodies and fusion proteins reach USD 1,649.09 Million by 2035, roughly two-thirds of regional revenue, with rheumatology and systemic autoimmune diseases (USD 490.72 Million) the second-largest therapy area after allergy, dermatology and immunologic disorders. Therapeutic peptides and proteins — insulin, GLP-1 and dual GIP/GLP-1 agonists — reach USD 518.24 Million at a faster 13.35% CAGR as generic semaglutide and biosimilar insulins enter through ANVISA and COFEPRIS approvals. Reusable systems (14.17% CAGR) grow faster than the regional market for cost as much as sustainability reasons.

Market Drivers and Restraints in Latin America

• Driver — diagnosis-gap conversion. As screening for diabetes, obesity and autoimmune disease widens, untreated chronic disease converts into injectable-therapy demand, led by Brazil.
• Driver — widening insurance coverage of biologics. Colombia's above-average growth tracks expanding coverage; the same mechanism operates across the region's middle-income markets.
• Driver — biosimilar and generic entry. Sun Pharma's ANVISA semaglutide approval, Zydus's COFEPRIS biosimilar approvals and the broader pipeline of Celltrion, Samsung Bioepis, Fresenius Kabi, Biocon Biologics and Lupin bring device presentations into price-sensitive markets.
• Driver — pooled procurement. The PAHO Strategic Fund and WHO prequalification channel give lower-income markets an access route for GLP-1 and insulin products.
• Restraint — macroeconomic volatility and affordability. Currency swings (Argentina in particular) and the availability discount between listed and accessible prices constrain premium presentations; the report's price chapter addresses emerging-market price sources and methodology.
• Restraint — regulatory fragmentation. ANVISA, ANMAT, INVIMA and ISP each require local registration and documentation for combination products, multiplying qualification cost for a single presentation.
• Restraint — limited local manufacturing. Dependence on imported devices exposes the region to global capacity bottlenecks and tariff-driven shifts in where platform specialists place capacity.

Competitive Landscape

Multinational pharma platform users — Novo Nordisk, Eli Lilly, Sanofi, AbbVie, Pfizer, AstraZeneca, Johnson & Johnson and UCB — lead branded autoinjector revenue, while biosimilar and generic entrants (Sun Pharmaceutical, Zydus Lifesciences, Celltrion, Samsung Bioepis, Fresenius Kabi, Viatris, Lupin, Aurobindo, Biocon Biologics, Amneal) drive volume growth. Devices are supplied by SHL Medical, Ypsomed, Owen Mumford / embecta, Gerresheimer, Haselmeier, Nemera, Elcam and Kindeva, with BD, West Pharmaceutical Services, SCHOTT Pharma, Nipro and Terumo anchoring primary containers. The report profiles 151 companies across 15 chapters with company details, financials, product summary and recent developments.

Report Scope — Latin America

Key Questions Answered

• How large is the Latin America autoinjectors market and how fast will Brazil, Argentina, Colombia and Chile each grow to 2035?
• Which biosimilar and generic GLP-1 approvals (ANVISA, COFEPRIS) are bringing new autoinjector presentations into the region, and who supplies the devices?
• How do affordability, currency volatility and the availability discount shape which architectures and container sizes win in each country?
• What role do PAHO pooled procurement and WHO prequalification play in access for lower-income markets?
• Which device makers, biosimilar companies and primary-container suppliers are best positioned as the region's biologic coverage widens?

This regional report is drawn from the Global Autoinjectors Market report. Related coverage: North America Autoinjectors Market report, Europe Autoinjectors Market report, Asia-Pacific Autoinjectors Market report and Middle East & Africa autoinjectors market reports.